GlassScriptPrepare for your visit
Marshall P Hyden
Cardiovascular Disease · Omaha, NE · NPI 1134354368
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$3,727.50
in general payments reported to CMS, 2019-2025 · $2,286 in 2025
The $2,286 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Who reported paying
General payments only, top 6 by amount.
- Alnylam Pharmaceuticals INC. $2,607.10
- Abbott Laboratories $395.28
- Medtronic Vascular, INC. $275.94
- Pfizer INC. $171.14
- Astrazeneca Pharmaceuticals LP $124.56
- Novartis Pharmaceuticals Corporation $81.46
Drugs and devices associated with these payments
Amvuttra Thoratec Heartmate 3 Lvas Implant Kit Cardiomems Entresto Leqvio Wainua Inspire Vyndaqel Kerendia
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Marshall Hyden listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/1399258/marshall-p-hyden